The rate-limiting enzyme of the mevalonate pathway leading to cholesterol synthesis is hydroxymethylglutarate-coenzyme A reductase, and this enzyme is both regulated by cholesterol levels [36,37] and is diagnostic of a recently identified class of poor prognosis apocrine breast cancers that were both ER-α and progesterone receptor negative [38]. The gene discussed is ESR1; the disease is breast cancer.